Thought Leadership
Amended FRE 702 on Expert Testimony Effective December 1, 2023
IP Litigator
Strategic Use of Evidence at the Patent Trial and Appeal Board
Practical Law
FTC Challenges More Than 100 Patents as Improperly Listed in Orange Book
Fish & Richardson
District of Delaware Finds Allergan Patents Invalid for Lack of Written Description and Obviousness-Type Double Patenting in Allergan v. MSN Labs
Legal Alert: EPO Enlarged Board of Appeal Raises Bar for Challenging Priority Claims at the EPO
Texas Patent Litigation Monthly Wrap-Up: October 2023
District of Delaware Finds Non-Orange Book-Listed Patents Subject to the Same Pleading Standard as Listed Patents in ANDA Infringement Suit
Fish & Richardson